Your browser doesn't support javascript.
Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients.
Hu, Zhong-Jie; Xu, Jia; Yin, Ji-Ming; Li, Li; Hou, Wei; Zhang, Li-Li; Zhou, Zhen; Yu, Yi-Zhou; Li, Hong-Jun; Feng, Ying-Mei; Jin, Rong-Hua.
  • Hu ZJ; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Xu J; Department of Immunology, Centre for Immunotherapy, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  • Yin JM; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Li L; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Hou W; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Zhang LL; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Zhou Z; Deepwise AI Lab, Beijing, China.
  • Yu YZ; Deepwise AI Lab, Beijing, China.
  • Li HJ; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Feng YM; Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Jin RH; Beijing Youan Hospital, Capital Medical University, Beijing, China.
Front Immunol ; 11: 585647, 2020.
Article in English | MEDLINE | ID: covidwho-874483
ABSTRACT
Cytokine storm resulting from SARS-CoV-2 infection is one of the leading causes of acute respiratory distress syndrome (ARDS) and lung fibrosis. We investigated the effect of inflammatory molecules to identify any marker that is related to lung fibrosis in coronavirus disease 2019 (COVID-19). Seventy-six COVID-19 patients who were admitted to Youan Hospital between January 21 and March 20, 2020 and recovered were recruited for this study. Pulmonary fibrosis, represented as fibrotic volume on chest CT images, was computed by an artificial intelligence (AI)-assisted program. Plasma samples were collected from the participants shortly after admission, to measure the basal inflammatory molecules levels. At discharge, fibrosis was present in 46 (60.5%) patients whose plasma interferon-γ (IFN-γ) levels were twofold lower than those without fibrosis (p > 0.05). The multivariate-adjusted logistic regression analysis demonstrated the inverse association risk of having lung fibrosis and basal circulating IFN-γ levels with an estimate of 0.43 (p = 0.02). Per the 1-SD increase of basal IFN-γ level in circulation, the fibrosis volume decreased by 0.070% (p = 0.04) at the discharge of participants. The basal circulating IFN-γ levels were comparable with c-reactive protein in the discrimination of the occurrence of lung fibrosis among COVID-19 patients at discharge, unlike circulating IL-6 levels. In conclusion, these data indicate that decreased circulating IFN-γ is a risk factor of lung fibrosis in COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Pulmonary Fibrosis / Interferon-gamma / Coronavirus Infections Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.585647

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Pulmonary Fibrosis / Interferon-gamma / Coronavirus Infections Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.585647